cardiovascular-agents and Leukemia-P388

Topics: Animals; Cardiovascular Agents; Cyclooctanes; Doxorubicin; Drugs, Chinese Herbal; Free Radical Scavengers; Leukemia P388; Lignans; Malondialdehyde; Mitochondria, Heart; Phenanthrenes; Polycyclic Compounds

The effects of certain compounds on the in vitro growth rate and the sensitivity to doxorubicin of P388 murine leukaemia cell line and of a doxorubicin-resistant subline (P388/ADR) were studied. The calcium channel blocking activity of these compounds was evaluated by measuring their effects on the sodium-dependent and membrane potential-dependent calcium uptake in synaptic plasma membrane vesicles. At non-inhibitory concentrations, verapamil, dipyridamole, meclizine and nicardipine were highly active in restoring the sensitivity to doxorubicin of P388/ADR cells. Moderately active were propranolol, N-(beta-diethylaminoethyl)-N-(beta-hydroxy-beta-phenylethyl)-2,5-dich loranaline (MDL-6792), thioridazine and chlorocyclizine, while nifedipine, guanethidine, phentolamine, chloroquine and papaverine had zero or only minimal synergistic activity to doxorubicin in this cell line. Doxorubicin synergistic activity could not be demonstrated in the parent drug-sensitive cell line. No sodium-dependent or membrane potential-dependent calcium uptake could be demonstrated in vesicles prepared from plasma membranes of either cell line. There is no correlation between the ability of these compounds to inhibit calcium uptake in synaptic vesicles and their potency in restoring the sensitivity of P388/ADR cells to doxorubicin.

Topics: Animals; Calcium; Cardiovascular Agents; Cell Line; Cell Membrane; Doxorubicin; Drug Resistance; Drug Synergism; Leukemia P388; Leukemia, Experimental; Mice; Synaptic Vesicles